The whooping cough 15 vaccine produced by MSD Pharmaceutical Group (USA) with advanced technology, effectively protects against strains of whooping cough bacteria 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F causing many invasive whooping cough diseases such as pneumonia, meningitis, non-invasive hemorrological and whooping cough infections such as pneumonia, mediastinal ear inflammation and sinusitis... The vaccine is used for children aged 2 months and over ( earliest from 6 weeks old) and adults, creating a long-term immune response, while reducing the rate of healthy people carrying the pathogens and reducing the risk of spreading the disease in the community.
According to Dr. Bach Thi Chinh, Medical Director of the VNVC Vaccination System, whooping cough is a dangerous infectious disease for both children and adults. Currently, there are many types of vaccine against against therapeutic brittle spleen in the world that help increase protection against this dangerous bacteria. Therefore, experts around the world recommend that people need to be vaccinated early and fully, combining many types of vaccine against plage in many different generations to achieve the best protection effect.
Vietnam has another high-tech vaccine, increasing the strain of frontal spray is a new weapon, adding to the strength of preventing infectious diseases for children and adults in our country. This combination helps strengthen disease prevention and cover other dangerous strains of plaque bacteria in the vaccine, said Dr. Chinh.
At the event, Dr. Phan Trong Giao, Medical Director of MSD Vietnam, said: MSD is proud to have a long history in the field of pediatrics and prevention of therapeutic bronchitis. Over the years, MSD vaccines have contributed to protecting the health of millions of children around the world. We are confident that the strawberry 15 vaccine with a wide range of pathogens and good immunity will provide a solid foundation to help protect Vietnamese people, especially young children, from the burden of strawberries.
According to the manufacturer, the cau 15 vaccine has been approved in 65 countries and officially used in more than 40 countries worldwide, since 2022.
Thus, along with the 10th, 13th and 23rd bridge vaccines, VNVC's addition of the 15th bridge vaccine to serve Vietnamese people is in line with the general trend of the world, focusing on preventing dangerous respiratory diseases in children and adults, with a rapid spread rate in the context of strong social and trade development as at present.
Depending on the vaccination time and the epidemic conditions of each locality, doctors will advise on the optimal straw vaccination type and suitable for the age of the vaccinated person. However, it is recommended to get vaccinated against plage vaccination as soon as possible as children reach vaccination age to protect against increasingly dangerous diseases caused by plage, including pneumonia, meningitis and sepsis...
The launch of the vaccine to prevent 15 strains of straw bacteria once again affirms VNVC's mission of providing Vietnam with many important vaccines along with safe, high-quality, affordable vaccination services, vaccines stored in a refrigeration system, cold chains that meet international standards GSP, ready to meet the vaccination needs of millions of people nationwide.
Over the past 8 years, in addition to the 15th vaccine, VNVC has joined many of the world's leading pharmaceutical companies to bring dozens of new generation vaccines for Vietnam, increasing the chances of approaching the horizontal and timely vaccine compared to developed countries in the world for people. Only in 2024 and 2025, VNVC deployed 4 vaccines for children and adults including the new generation B brain brain vaccine, 23 -vaccine, dengue vaccine and neurotransmitter vaccine. In 2025, VNVC continues to negotiate with manufacturers and distributors to return and deploy other important vaccines for children and adults.
In particular, VNVC is aiming to master high-level vaccine production technology, proactively supplying domestically while preparing to build a VNVC Vaccine and Food Factory in Long An province with a scale of about 2,000 billion VND. The unit has reached an initial agreement to share experiences and transfer vaccine production technology with the world's leading pharmaceutical companies such as Sanofi and Pfizer.
